# Double-blind Comparative Study of SYR-472

> **NCT01632007** · PHASE3 · COMPLETED · sponsor: **Takeda** · enrollment: 245 (estimated)

## Conditions studied

- Diabetes Mellitus

## Interventions

- **DRUG:** SYR-472
- **DRUG:** Alogliptin 25 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01632007
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-05-01
- **Primary completion:** 2013-07-01
- **Final completion:** 2013-07-01
- **Target enrollment:** 245 (ESTIMATED)
- **Last updated:** 2023-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01632007

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01632007, "Double-blind Comparative Study of SYR-472". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT01632007. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*